Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
1.045
-0.015 (-1.42%)
Mar 9, 2026, 1:54 PM EDT - Market open
Oncolytics Biotech Employees
Oncolytics Biotech had 28 employees as of December 31, 2024. The number of employees decreased by 1 or -3.45% compared to the previous year.
Employees
28
Change
-1
Growth
-3.45%
Revenue / Employee
n/a
Profits / Employee
-$904,312
Market Cap
112.45M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2022 | 29 | 3 | 11.54% |
| Dec 31, 2021 | 26 | 1 | 4.00% |
| Dec 31, 2020 | 25 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Codexis | 188 |
| Gossamer Bio | 145 |
| Inovio Pharmaceuticals | 134 |
| Fortress Biotech | 101 |
| Korro Bio | 87 |
| Precision BioSciences | 67 |
| Equillium | 35 |
| Gain Therapeutics | 25 |
ONCY News
- 7 days ago - Oncolytics Biotech® Launches Randomized Colorectal Cancer Study - GlobeNewsWire
- 13 days ago - Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer - GlobeNewsWire
- 4 weeks ago - Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer - GlobeNewsWire
- 7 weeks ago - Oncolytics Biotech® Announces Results of Special Meeting of Shareholders - GlobeNewsWire
- 7 weeks ago - Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 2 months ago - Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer - GlobeNewsWire
- 2 months ago - Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada - GlobeNewsWire
- 2 months ago - Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings - Business Wire